{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:09:09Z","timestamp":1790554149874,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neuroblastoma (NB), a malignant extracranial solid tumor originating from the sympathetic nervous system, exhibits poor prognosis in high-risk cases, with a 5-year overall survival rate below 50%. Glycolysis has been implicated in NB pathogenesis, and targeting glycolysis-related pathways shows therapeutic potential. This study investigates the role of the glycolysis-associated gene ALDOC in NB pathogenesis and its impact on chemotherapy sensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Transcriptomic data from NB patients were analyzed to identify ALDOC as an independent risk factor for high-risk NB. Protein expression levels of ALDOC were assessed in NB cells versus normal cells using immunoblotting. Functional experiments, including proliferation and migration assays, were conducted in ALDOC-interfered NB cell lines. Glycolytic activity was evaluated by measuring glucose uptake, lactate production, and ATP generation. Additionally, the sensitivity of ALDOC-downregulated NB cells to cisplatin and cyclophosphamide was tested to explore its role in chemotherapy response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ALDOC was identified as a high-risk prognostic marker in NB, with elevated protein expression in NB cells compared to normal controls. Silencing ALDOC significantly inhibited NB cell proliferation and migration. Glycolytic activity was markedly reduced in ALDOC-downregulated cells, evidenced by decreased glucose uptake, lactate production, and ATP levels. Furthermore, ALDOC suppression enhanced NB cell sensitivity to cisplatin and cyclophosphamide, suggesting a glycolysis-dependent mechanism underlying chemotherapy resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings highlight ALDOC as a critical driver of NB progression through glycolysis acceleration, with implications for therapeutic targeting. The observed increase in chemotherapy sensitivity upon ALDOC inhibition underscores its potential as a biomarker for treatment optimization. However, the complexity of glycolysis regulation, involving multiple genes and pathways, necessitates further mechanistic studies to clarify ALDOC\u2019s specific role. Despite this limitation, our work emphasizes the importance of aerobic glycolysis in NB pathogenesis and provides a foundation for developing novel therapeutic strategies targeting ALDOC or associated pathways. Future research should explore interactions between ALDOC and other glycolytic regulators to refine combinatorial treatment approaches.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1573815","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:10:49Z","timestamp":1744863049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["ALDOC promotes neuroblastoma progression and modulates sensitivity to chemotherapy drugs by enhancing aerobic glycolysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunpeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YaXuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyou","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0686-8","article-title":"11q deletion in neuroblastoma: a review of biological and clinical implications","volume":"16","author":"Mlakar","year":"2017","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00919","article-title":"Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the children\u2019s oncology group study ANBL0531","volume":"37","author":"Twist","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","article-title":"WHO classification of tumours: paediatric tumours","author":"Alaggio","year":"2022","journal-title":"Int Agency Res Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children\u2019s oncology group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1265","article-title":"Spontaneous regression of localized neuroblastoma detected by mass screening","volume":"16","author":"Yamamoto","year":"1998","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/scd.2020.0142","article-title":"Mesenchymal stromal cells in neuroblastoma: exploring crosstalk and therapeutic implications","volume":"30","author":"Hochheuser","year":"2021","journal-title":"Stem Cells Dev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199905000-00005","article-title":"Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival","volume":"21","author":"DuBois","year":"1999","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-011514-023121","article-title":"Neuroblastoma: molecular pathogenesis and therapy","volume":"66","author":"Louis","year":"2015","journal-title":"Annu Rev Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2020","journal-title":"Medicinal Res Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14737140.2017.1364995","article-title":"Anti-GD2 immunotherapy for neuroblastoma","volume":"17","author":"Sait","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2024.02.004","article-title":"The therapeutic effect of MSCs and their extracellular vesicles on neuroblastoma","volume":"187","author":"Karami Fath","year":"2024","journal-title":"Prog Biophys Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"115696","DOI":"10.1016\/j.bcp.2023.115696","article-title":"A molecular basis of tumor metastasis and current approaches to decode targeted migration-promoting events in pediatric neuroblastoma","volume":"215","author":"Corallo","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/thno.28992","article-title":"LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt\/mTOR signaling pathway","volume":"9","author":"Zheng","year":"2019","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.30224","article-title":"TBC1D8 amplification drives tumorigenesis through metabolism reprogramming in ovarian cancer","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.285","article-title":"Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment","volume":"5","author":"Ciavardelli","year":"2014","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiology.194.2.7824731","article-title":"Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies","volume":"194","author":"Shulkin","year":"1995","journal-title":"Radiology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.545","article-title":"Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate","volume":"6","author":"Nilsson","year":"2015","journal-title":"Cell Death Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00440-07","article-title":"Hypoxia-inducible factor 1 and dysregulated c-myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1","volume":"27","author":"Kim","year":"2023","journal-title":"Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1267\/ahc.24-00044","article-title":"Fructose-bisphosphate aldolase C expression is associated with poor prognosis and stemness in gastric cancer","volume":"57","author":"Ishikawa","year":"2024","journal-title":"Acta Histochem Et Cytochem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/pin.13200","article-title":"Overexpression of aldolase, fructose-bisphosphate C and its association with spheroid formation in colorectal cancer","volume":"72","author":"Maruyama","year":"2022","journal-title":"Pathol Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12032-024-02470-x","article-title":"Diverse roles of aldolase enzymes in cancer development, drug resistance and therapeutic approaches as moonlighting enzymes","volume":"41","author":"Tang","year":"2024","journal-title":"Med Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216617","article-title":"Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma","volume":"588","author":"Chou","year":"2024","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.05.003","article-title":"Roles of aldolase family genes in human cancers and diseases","volume":"29","author":"Chang","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205038","article-title":"ALDOC promotes non-small cell lung cancer through affecting MYC-mediated UBE2N transcription and regulating Wnt\/beta-catenin pathway","volume":"15","author":"Shang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-164","article-title":"Aldolase positively regulates of the canonical Wnt signaling pathway","volume":"13","author":"Caspi","year":"2014","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112118","article-title":"MUC16 C-terminal binding with ALDOC disrupts the ability of ALDOC to sense glucose and promotes gallbladder carcinoma growth","volume":"394","author":"Fan","year":"2020","journal-title":"Exp Cell Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.c.7181269.v2","article-title":"Breast cancer stem cells secrete MIF to mediate tumor metabolic reprogramming that drives immune evasion","volume":"84","author":"Yan","year":"2024","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","article-title":"and DeBerardinis RJ: Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41423-021-00727-3","article-title":"The therapeutic implications of immunosuppressive tumor aerobic glycolysis","volume":"19","author":"Reinfeld","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Pearson","year":"2008","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children\u2019s oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2012.06.004","article-title":"Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells","volume":"1826","author":"Chen","year":"2012","journal-title":"Biochim Biophys Acta (BBA) Reviews Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120162","article-title":"Targeting glucose metabolism for cancer therapy","volume":"209","author":"Hamanaka","year":"2012","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist Update"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.12.009","article-title":"Glycolysis-induced drug resistance in tumors\u2014A response to danger signals","volume":"23","author":"Marcucci","year":"2021","journal-title":"Neoplasia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.613.65.2","article-title":"Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia","volume":"65","author":"Xu","year":"2005","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310722200","article-title":"Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization","volume":"278","author":"Gregory","year":"2003","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Yeh","year":"2004","journal-title":"Nat Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1332941","DOI":"10.1080\/20013078.2017.1332941","article-title":"Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells","volume":"6","author":"Nakata","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1597614","DOI":"10.1080\/20013078.2019.1597614","article-title":"Exosomes from N-Myc amplified neuroblastoma cells induce migration and confer chemoresistance to non-N-Myc amplified cells: implications of intra-tumour heterogeneity","volume":"8","author":"Fonseka","year":"2019","journal-title":"J Extracell Vesicles"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00806-1","article-title":"Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma","volume":"53","author":"Jansky","year":"2021","journal-title":"Nat Genet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0740","article-title":"Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha","volume":"70","author":"Qing","year":"2010","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113032","article-title":"Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma","volume":"150","author":"Bishayee","year":"2022","journal-title":"Biomed Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:10:51Z","timestamp":1744863051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1573815"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1573815","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"1573815"}}